LEXICON PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
LXRX$1.86+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(In thousands, except per share amounts)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Revenues: | |||
| Net product revenue | $4,647 | $6,001 | $1,110 |
| Licensing revenue | 45,000 | 25,000 | — |
| Royalties and other revenue | 156 | 80 | 94 |
| Total revenues | 49,803 | 31,081 | 1,204 |
| Operating expenses: | |||
| Cost of sales | 274 | 616 | 85 |
| Research and development, including stock-based compensation of $6,289, $5,839 and $5,139 respectively | 61,121 | 84,480 | 58,887 |
| Selling, general and administrative, including stock-based compensation of $6,228, $7,660 and $9,201, respectively | 37,319 | 143,102 | 113,982 |
| Total operating expenses | 98,714 | 228,198 | 172,954 |
| Loss from operations | (48,911) | (197,117) | (171,750) |
| Interest and other expense | (8,339) | (15,579) | (13,101) |
| Interest income and other | 6,909 | 12,293 | 7,732 |
| Net loss | $(50,341) | $(200,403) | $(177,119) |
| Net loss per common share, basic and diluted | $(0.14) | $(0.63) | $(0.80) |
| Weighted average common shares outstanding, basic and diluted | 363,053 | 320,031 | 221,130 |
| Other comprehensive loss: | |||
| Unrealized (loss) gain on investments | (89) | 88 | 459 |
| Comprehensive loss | $(50,430) | $(200,315) | $(176,660) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.